19 reports

  • HUGE MARKET POTENTIAL FOR BREAST CANCER MABS OWING TO PRODUCT APPROVALS

In Europe, one in eight women develop breast cancer in their lifetime.

  • Cancer
  • United States
  • World
  • Market Size
  • Seattle Genetics, Inc.
  • LIST OF PHASE III PIPELINE MOLECULES
  • LIST OF PHASE I PIPELINE MOLECULES

About Cancer Monoclonal Antibodies The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other...

  • Cancer
  • Monoclonal Antibody
  • Therapy
  • Amgen Inc.
  • Seattle Genetics, Inc.
  • Zarour HM, et al. (2003). Categories of tumor antigens. Cancer Medicine; 6th Edition
  • 8.1 REFERENCES

Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline Summary Cancer immunotherapy, which can predominantly be classed as a form of targeted therapy, drives an immune response against cancer cells. This...

  • Cancer
  • Cancer Immunotherapy
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • Seattle Genetics, Inc.
  • Executive Summary
  • B: ADC Pipeline Analysis, By Drug, Developer, Phase, Indication, Status

ABOUT ## IN ## CASES OF THIS CANCER ARE HER## POSITIVE.

  • Cancer
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Seattle Genetics, Inc.
  • Lymphoma drugs market in Americas
  • Lymphoma drugs market in EMEA

Lymphoma is one of the most prevalent forms of cancers, affecting huge population every year.

  • Cancer
  • Lymphoma
  • United States
  • Forecast
  • Seattle Genetics, Inc.
  • PIPELINE PORTFOLIO
  • MARKET DRIVERS

About Antibody Drug Conjugates ADCs, empowered monoclonal antibodies (mAbs), use chemical linkers with labile bonds to attach biologically active substances. ADCs target mAbs with the cancer killing ability of cytotoxic drugs, allowing sensitive discernment between healthy and diseased tissue. Antibodies are the proteins produced...

  • Cancer
  • Therapy
  • ImmunoGen, Inc.
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited
  • ADCS FOR BREAST CANCER
  • 6. KEY THERAPEUTIC AREAS

INTRODUCTION Since the first approval of MYLOTARG™ in 2000 and its subsequent withdrawal in the year 2010, the ADC market has evolved considerably. In the last seven years, the market has witnessed an increasing interest from drug developers and healthcare investors alike. Post the commercialization of ADCETRIS®...

  • Cancer
  • Clinical Trial
  • Pharmaceutical
  • Therapy
  • Seattle Genetics, Inc.
  • PIPELINE PORTFOLIO

About Monoclonal Antibodies Antibodies are the proteins produced by B-cells (in the bone marrow) in the immune system. These proteins attach themselves to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies, which attach themselves to different sites of an antigen. mAbs are monospecific,...

  • Cancer
  • Monoclonal Antibody
  • Therapy
  • Amgen Inc.
  • Seattle Genetics, Inc.

Hoffmann-La Roche Ltd. ## ## ## ## ## ## ## ## Amgen Inc. ## ## ## ## ## ## ## ## AbbVie Inc. ## ## ## ## ## ## ## ## Source: GlobalData' s Pharma eTrack Clinical Trials Database (*)Trials are taken for a time period of 1995 - 2015 2015 trials are taken as of Augu

  • Cancer
  • Clinical Trial
  • Hospital
  • Lymphoma
  • Seattle Genetics, Inc.
  • SALES MIX - US AND CANADA/INTERNATIONAL
  • TOTAL SALES (SEATTLE GENETICS AND TAKEDA) - GROWING STEADILY IN NICHE MARKET

ANNEXURE Our coverage list: ## cancer drugs ##.

  • Cancer
  • Lymphoma
  • Therapy
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited
  • 10.1 BIBLIOGRAPHY
  • ADCETRIS SWOT ANALYSIS, 2015

NATURE REVIEWS CANCER; ##(##): ##-##.

  • Cancer
  • Epidemiology
  • Therapy
  • World
  • Seattle Genetics, Inc.

This version of the DART molecule enables the cancer-fighting properties of the immune effector cells, such as T lymphocytes, to: (##) recognize and bind to structures expressed on a cancer cell, (##) recruit all types of cytotoxic, or cell killing, T cells, irrespective of

  • Cancer
  • Cell Therapy
  • Cellectis S.A.
  • Janssen Biotech, Inc.
  • Seattle Genetics, Inc.
  • Dec 07, 2017: Prolonged Progression-Free Survival Reinforces Tucatinib's Potential for Patients with Advanced HER2+ Metastatic Breast Cancer
  • Jan 10, 2017: Tucatinib (ONT-380) progressing in pivotal trial against HER2+ breast cancer

Summary Seattle Genetics Inc (Seattle Genetics) is a biotechnology company that develops and commercializes monoclonal antibody-based therapies for the treatment of cancer.The company’s lead product Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) indicated for the treatment of relapsed Hodgkin lymphoma...

  • Cancer
  • Therapy
  • United States
  • Company Financials
  • Seattle Genetics, Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • Seattle Genetics Inc, Major Products and Services
  • Section 2 - Company Analysis

SEA- CD## is under evaluation in a phase ## trial for the treatment of blood cancers and solid tumors.

  • Cancer
  • Therapy
  • United States
  • Company Financials
  • Seattle Genetics, Inc.
  • COPANLISIB HYDROCHLORIDE - DRUG PROFILE
  • Anaplastic Large Cell Lymphoma (ALCL) - Companies Involved in Therapeutics Development

Cisplatin is one of the most commonly utilized treatments for lung, breast and colon cancers.

  • Cancer
  • Lymphoma
  • United States
  • Product Initiative
  • Seattle Genetics, Inc.
  • BRENTUXIMAB VEDOTIN - DRUG PROFILE

THE DRUG CANDIDATE HAS POTENTIAL APPLICATIONS IN CANCER AND CANCER PAIN.

  • Autoimmune Disease
  • Cancer
  • Dermatological Condition
  • Musculoskeletal Disorder
  • Seattle Genetics, Inc.
  • Anaplastic Large Cell Lymphoma (ALCL) - Companies Involved in Therapeutics Development
  • ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) - DORMANT PROJECTS, H1 2016

Cisplatin is one of the most commonly utilized treatments for lung, breast and colon cancers.

  • Cancer
  • Lymphoma
  • United States
  • Product Initiative
  • Seattle Genetics, Inc.
  • ADC PIPELINE OF OXFORD BIOTHERAPEUTICS
  • ADDENDUM 3: ADCS IN IND-ENABLING STUDIES - 2/2

Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis This report describes and analyzes the situation of antibody-drug conjugates as of November 2015 regarding ADC pipeline, ADC technologies, ...

  • Cancer
  • Monoclonal Antibody
  • Therapy
  • United States
  • Seattle Genetics, Inc.